
Foghorn Therapeutics (FHTX) Stock Forecast & Price Target
Foghorn Therapeutics (FHTX) Analyst Ratings
Bulls say
Foghorn Therapeutics is a promising biotechnology company with a strong focus on developing innovative treatments for cancer by targeting specific proteins. Their partnerships and successful preclinical research showcase their potential for success. With a strong team and a growing pipeline, Foghorn Therapeutics is poised for growth and success in the biotech industry.
Bears say
Foghorn Therapeutics is currently facing several fundamental risks that could negatively impact its stock performance. These include upcoming milestones relating to its flagship program FHD-909, a lack of head-to-head preclinical data comparing FHD-909 against other SMARCA2 targeted molecules, and commercialization and pricing risk given increasing competition in the precision therapeutics biotechnology space. Additionally, the company is reliant on access to capital and may require additional funding through equity offerings, which could dilute shareholder value and negatively impact the stock price. Despite the potential for combination approaches with a SMARCA2 targeted therapy, data from rivals like Prelude suggest significant safety concerns and potentially limited efficacy of these drugs, presenting a further hurdle for the company to overcome. Overall, these fundamental risks lead to a negative outlook on Foghorn Therapeutics and its stock.
This aggregate rating is based on analysts' research of Foghorn Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Foghorn Therapeutics (FHTX) Analyst Forecast & Price Prediction
Start investing in Foghorn Therapeutics (FHTX)
Order type
Buy in
Order amount
Est. shares
0 shares